Doctors

Pharma Industry’s Job is NOT Disease Prevention. THAT’S YOUR JOB.

I’ve heard the argument, so have you. “Those evil pharma companies aren’t interested in prevention! They want people to get sick and stay sick because that’s how they make their money! On the drugs!” Recently I had railed against the pharma companies that are capitalizing on increasing trends of people using certain prescription drugs as [...]

Read the full article →

Most Doctors Don’t Recommend Their Own Profession

Dan Abshear Lately in the media, others have said and expressed concern about the apparent shortage of primary care doctors, most notably. Typically, the main reason stated for this shortage is lack of pay of this particular specialty compared with others chosen by potential physicians. Yet considering the additional attention of shortages of students in [...]

Read the full article →

Retail Clinics: Quick When You’re Sick

By Dan Abshear Recently in the media, issues have been addressed regarding the specialty of primary care or family practice doctors and the shortage of them in the U.S. In summary, reasons for the shortage that exists are due to the specialty not being that profitable for a doctor compared with other specialties. As a [...]

Read the full article →

Provenge and FDA’s Etiology For Not Approving

By Dan Abshear Terminal patients are those who are not expected to live due to usually illness such as advanced prostate cancer (cT3). If the patient has 6 months or less to live, those patients are considered terminally ill. Regardless, if a patient is terminal, they are without a cure or tolerable treatment for their [...]

Read the full article →

Patients Adrift in a Sea of Clinical Trials

By Sally Satel, M.D. On the front page of the Washington Post last week was a headline geared to spark the ire of those who have a congenital animus toward pharmaceutical companies–”Comparison of Schizophrenia Drugs Often Favors Firm Funding Study“. The Post article noted that, according to a recent study, nine out of ten head-to-head [...]

Read the full article →

← Previous Entries

Next Entries →